Related Experiment Video

Updated: Nov 4, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.4K

[NSCLC and new oncogenic mutations: Diagnosis and perspectives]

C Basse1, A Swalduz2, A Mc Leer3

  • 1Institut du thorax curie Montsouris, institut Curie, Paris, France.

Revue Des Maladies Respiratoires
|May 22, 2021
PubMed

Insights

Understanding molecular changes in non-small cell lung carcinoma (NSCLC) drives targeted therapy development. New biomarkers and innovative drugs are emerging for NSCLC treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Targeted therapies for non-small cell lung carcinoma (NSCLC) require understanding molecular carcinogenesis.
  • Knowledge of molecular aberrations in disease progression is crucial.
  • Development of molecular biology platforms is essential for identifying new biomarkers.

Purpose of the Study:

  • To review current and emerging techniques in cancer molecular biology platforms for NSCLC.
  • To highlight newly identified molecular abnormalities and their targeted therapies.

Main Methods:

  • Review of techniques used in routine cancer molecular biology platforms.
  • Review of novel techniques under development for biomarker discovery.
  • Analysis of clinical trial data for targeted drugs.

Main Results:

  • New molecular abnormalities identified in NSCLC include EGFR exon 20, HER2, MET, RET, BRAF, ROS1, and NTRK.
  • Targeted drugs are being developed and tested for these specific molecular alterations.
  • Biomarkers are becoming available to clinicians and biologists.

Conclusions:

  • Advancements in molecular biology platforms are enabling the identification of novel NSCLC biomarkers.
  • These biomarkers facilitate the development and application of targeted therapies.
  • Ongoing research into molecular abnormalities promises improved treatment strategies for NSCLC.
Keywords:
Biologie moléculaireCancers bronchiquesClinical trialsEssais cliniquesLung cancerMolecular biologyStade IVStage IVTargeted treatmentsTraitement ciblés

More Related Videos

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.7K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
51.4K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.5K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.8K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
13.4K